Draft:SciBase Inc
 | A major contributor to this article appears to have a close connection with its subject. (September 2024) |
Submission declined on 12 September 2024 by DoubleGrazing (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: Primary sources do not establish notability per WP:NCORP. DoubleGrazing (talk) 09:40, 12 September 2024 (UTC)
| Industry | Medical Technology |
|---|---|
| Founded | 1998 |
| Products | Nevisense |
| Website | https://scibase.com |
SciBase is a Swedish medical technology company founded in 1998 by Stig Ollmar. The company specializes in developing technologies for early detection and prevention in dermatology, based on over 20 years of research conducted at the Karolinska Institute in Stockholm, Sweden.[1] SciBase is listed on the Nasdaq First North Growth Market since June 2, 2015.[2]
History
[edit]SciBase was established in 1998 to develop innovative tools for dermatological diagnostics. It was founded by Stig Ollmar, an Associate Professor in Medical Engineering at the Karolinska Institute, with extensive experience in bioelectrical research.[3] Ollmar served as the company's managing director for the first seven years.[3]
Technology and Products
[edit]SciBase develops and commercializes Nevisense, a platform that combines artificial intelligence (AI) and Electrical Impedance Spectroscopy (EIS) technology for the detection of skin diseases such as melanoma, skin cancer, and keratinocytic tumors, as well as for assessing the skin barrier.[1] Nevisense is designed to assist healthcare professionals in making diagnostic decisions in dermatology.[4] It’s the only FDA approved diagnostic device for melanoma detection In US.[5]
Market Presence
[edit]The company's main product, Nevisense, is available in several international markets, including Belgium, Germany, Austria, Switzerland, the Nordic countries, and the United States.[6] The company is headquartered in Stockholm, Sweden.[1]
Leadership
[edit]The Chairman of the Board, Jesper Høiland, was appointed on June 13, 2024.[7] He has over 25 years of experience in senior roles within global pharmaceutical companies, including Ascendis Pharma, Radius Health, and Novo Nordisk.[7] Pia Renaudin has served as the CEO of SciBase since October 1, 2023, br
inging extensive experience from the life sciences sector, with a focus on marketing and sales.[4]
References
[edit]- ^ a b c "ABOUT SCIBASE - Scibase". Scibase - gy. 2017-11-01. Retrieved 2024-09-12.
- ^ "SCIB, SciBase Holding". Nasdaq. 12 September 2024. Retrieved 11 September 2024.
{{cite web}}: CS1 maint: url-status (link) - ^ a b "Founder of SciBase - Scibase". Scibase - gy. 2023-01-11. Retrieved 2024-09-12.
- ^ a b "WE ARE SCIBASE - Scibase". Scibase - gy. 2017-11-02. Retrieved 2024-09-12.
- ^ "FDA Executive Summary Reclassification Panel Meeting on Skin Lesion Analyzers". FDA Gov. 29 July 2022. Retrieved 20 August 2024.
- ^ "AVAILABLE MARKETS - Scibase". Scibase - gy. 2017-11-01. Retrieved 2024-09-12.
- ^ a b "SciBase welcomes new chairman and thanks the former". Scibase. 2024-06-13. Retrieved 2024-09-12.
- in-depth (not just brief mentions about the subject or routine announcements)
- reliable
- secondary
- strictly independent of the subject
Make sure you add references that meet all four of these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Wikipedia.